824 related articles for article (PubMed ID: 14763888)
21. Risk of relapse in leprosy after fixed-duration multidrug therapy.
Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
[TBL] [Abstract][Full Text] [Related]
22. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
[TBL] [Abstract][Full Text] [Related]
23. An 8-12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multi-drug therapy.
Desikan KV; Sundaresh P; Tulasidas I; Rao PV
Lepr Rev; 2008 Sep; 79(3):303-10. PubMed ID: 19009979
[TBL] [Abstract][Full Text] [Related]
24. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
[TBL] [Abstract][Full Text] [Related]
25. Relapse in MB leprosy patients treated with 24 months of MDT in south west China: a short report.
Shen J; Liu M; Zhang J; Su W; Ding G
Lepr Rev; 2006 Sep; 77(3):219-24. PubMed ID: 17172002
[TBL] [Abstract][Full Text] [Related]
26. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
27. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
[TBL] [Abstract][Full Text] [Related]
28. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
Biswas S; Mondal KK
Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
[TBL] [Abstract][Full Text] [Related]
29. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group.
Jamet P; Ji B
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):525-35. PubMed ID: 1299707
[TBL] [Abstract][Full Text] [Related]
30. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
31. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
32. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
33. A study of relapse after MDT in a district in West Bengal, India.
Haldar A; Mahapatra BS; Mundle M; Haldar S; Saha AK
Indian J Lepr; 2003; 75(1):1-8. PubMed ID: 15253389
[TBL] [Abstract][Full Text] [Related]
34. Relapse of leprosy after multidrug therapy.
Dasananjali K
J Med Assoc Thai; 1996 Oct; 79(10):635-9. PubMed ID: 8996998
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
36. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
37. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
38. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
39. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
40. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
